Cargando…

Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Prognostic Markers for Extensive Disease of Small Cell Lung Cancer

BACKGROUND: The Royal Marsden Hospital prognostic score (RMH score) and the Gustave Roussy immune score (GRIm-score) were developed in order to select more suitable patient for phase I trials. Lactate dehydrogenase (LDH) and serum albumin concentration are common risk factors to these two systems. A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minami, Seigo, Ihara, Shouichi, Komuta, Kiyoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239571/ https://www.ncbi.nlm.nih.gov/pubmed/32494316 http://dx.doi.org/10.14740/wjon1275

Ejemplares similares

Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer
por: Minami, Seigo, et al.
Publicado: (2019)

Gustave Roussy Immune Score Is a Prognostic Factor for Chemotherapy-Naive Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor Receptor
por: Minami, Seigo, et al.
Publicado: (2019)

Prognostic value of modified-Gustave-Roussy Immunity Score in resectable proximal gastric cancer
por: Shi, Yujing, et al.
Publicado: (2023)

Gustave Roussy Immune Score (GRIm-Score) is a prognostic marker in patients with resectable esophageal squamous cell carcinoma
por: Feng, Ji-Feng, et al.
Publicado: (2020)

Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2017)

Prognostic significance of the Gustave Roussy immune (GRIm) score in cancer patients: a meta-analysis
por: Sun, Ke-Xin, et al.
Publicado: (2023)

Pretreatment Lung Immune Prognostic Index Is a Prognostic Marker of Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Minami, Seigo, et al.
Publicado: (2019)

Gustave Roussy Immune Score as a Novel Prognostic Scoring System for Colorectal Cancer Patients: A Propensity Score Matching Analysis
por: Tian, Shan, et al.
Publicado: (2021)

Pretreatment Lymphocyte to Monocyte Ratio as a Prognostic Marker for Advanced Pulmonary Squamous Cell Carcinoma Treated With Chemotherapy
por: Minami, Seigo, et al.
Publicado: (2018)

Gustave Roussy immune score is a prognostic marker in patients with small cell lung cancer undergoing immunotherapy: a real-world retrospective study
por: Shangguan, Jian, et al.
Publicado: (2023)

Lymphocyte to Monocyte Ratio and Modified Glasgow Prognostic Score Predict Prognosis of Lung Adenocarcinoma Without Driver Mutation
por: Minami, Seigo, et al.
Publicado: (2018)

Sarcopenia and Visceral Adiposity Are Not Independent Prognostic Markers for Extensive Disease of Small-Cell Lung Cancer: A Single-Centered Retrospective Cohort Study
por: Minami, Seigo, et al.
Publicado: (2020)

Development and Validation of a Prognostic Score for Hepatocellular Carcinoma Patients in Immune Checkpoint Inhibitors Therapies: The Hepatocellular Carcinoma Modified Gustave Roussy Immune Score
por: Li, Yongjiang, et al.
Publicado: (2022)

Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2016)

Low Body Mass Index Is an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Minami, Seigo, et al.
Publicado: (2019)

The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Outcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma
por: Minami, Seigo, et al.
Publicado: (2016)

Sarcopenia and Visceral Adiposity Did Not Affect Efficacy of Immune-Checkpoint Inhibitor Monotherapy for Pretreated Patients With Advanced Non-Small Cell Lung Cancer
por: Minami, Seigo, et al.
Publicado: (2020)

Bilateral germ-cell tumours: 22-year experience at the Institut Gustave Roussy
por: Theodore, Ch, et al.
Publicado: (2004)

Feasibility and first reports of the MATCH-R repeated biopsy trial at Gustave Roussy
por: Recondo, Gonzalo, et al.
Publicado: (2020)

Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor
por: Minami, Seigo, et al.
Publicado: (2017)

The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab
por: Lenci, Edoardo, et al.
Publicado: (2021)

High neutrophils and low lymphocytes percentages in bronchoalveolar lavage fluid are prognostic factors of higher in-hospital mortality in diffuse alveolar hemorrhage
por: Kanaoka, Kensuke, et al.
Publicado: (2021)

Prognostic factors and treatment outcomes in patients with Small Bowel Adenocarcinoma (SBA): The Royal Marsden Hospital (RMH) experience
por: Khan, Khurum, et al.
Publicado: (2015)

1688P Outcome of older cancer patients infected with COVID-19 at Gustave Roussy Cancer Center
por: Hauchecorne, M., et al.
Publicado: (2020)

Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study
por: Minami, Seigo, et al.
Publicado: (2017)

Pulmonary Adenosquamous Cell Carcinoma With Systemic Lymphadenopathy due to Immunoglobulin G4-Related Disease: A Case Report
por: Ikebe, Saori, et al.
Publicado: (2021)

Treatment of Epithelioid Sarcoma at the Royal Marsden Hospital
por: Livi, L., et al.
Publicado: (2003)

Impact of missing individual patient data on 18 meta-analyses of randomised trials in oncology: Gustave Roussy experience
por: Fayard, Florence, et al.
Publicado: (2018)

Helping patients make informed decisions. Two-year evaluation of the Gustave Roussy prostate cancer multidisciplinary clinic
por: Patrikidou, Anna, et al.
Publicado: (2018)

Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy
por: Pein, F, et al.
Publicado: (2004)

41P The SARS-CoV-2 vaccine and enrollment of patients with cancer in phase I trials: The experience at Institute Gustave Roussy
por: Belcaid, L., et al.
Publicado: (2022)

Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital.
por: Swerdlow, A. J., et al.
Publicado: (1997)

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
por: Arkenau, H-T, et al.
Publicado: (2008)

Reply: Clinical outcome and prognostic factors for patients treated within a phase I study: the Royal Marsden Hospital Experience
por: Olmos, D, et al.
Publicado: (2008)

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience
por: Tirelli, U
Publicado: (2008)

Dr. Marsden
Publicado: (1836)

The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil.
por: Crawley, C., et al.
Publicado: (1998)

Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience
por: Maruzzo, Marco, et al.
Publicado: (2015)

Successful Treatment of Allergic Bronchopulmonary Aspergillosis Using a Combination of Inhaled Fluticasone Furoate/Vilanterol and Oral Voriconazole
por: Nishimatsu, Kanako, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_atf8rjhkbq6up82d1cg9m91ukh